Premium
Decitabine as a conditioning regimen in haploidentical stem cell transplantation for refractory acute myeloid leukaemia
Author(s) -
Zhang C.,
Chen X.H.,
Liu J.,
Gao L.,
Liu Y.,
Gao L.,
Kong P.Y.,
Zhang X.
Publication year - 2015
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12251
Subject(s) - decitabine , medicine , cebpa , regimen , hematopoietic stem cell transplantation , oncology , transplantation , refractory (planetary science) , cytarabine , azacitidine , npm1 , chemotherapy , biology , karyotype , biochemistry , gene expression , chromosome , astrobiology , gene , dna methylation , mutation
Summary What is known and Objective Chemotherapy can increase treatment‐related mortality associated with future haematopoietic stem cell transplantation ( HSCT ) for patients with relapsed/refractory acute myeloid leukaemia ( AML ). There is usually insufficient time to find a suitable unrelated donor for these patients. We report on the use of decitabine, a DNA methyltransferase inhibitor as a conditioning regimen for a patient undergoing HSCT . Case summary Our patient was a 21‐year‐old male diagnosed with AML ‐M1 with 84·5% blast cells and a normal karyotype. His risk stratum was intermediate, without specific mutations of FLT 3/ ITD , NPM 1, CEBPA and C‐kit . He underwent successful haploidentical HSCT using decitabine, a conditioning regimen. What is new and conclusion We present the first report of a patient with refractory AML (with 58% blast cells) treated successfully with decitabine as a conditioning regimen in haploidentical HSCT .